Piper Sandler analyst Biren Amin discusses recent news in ATTR cardiomyopathy, ophthalmology, Duchenne muscular dystrophy, and more

blonca9
Oct 22, 2024
1 min read

Biren Amin joins BiotechTV from the NYSE and discusses BridgeBio, Ocular Therapeutix, Apellis, Sarepta, Solid Bio, Cargo Therapeutics, Allogene, Arcellx, and Elevation Oncology, and more.

Recent Posts

See All

ASGCT 2025: Physicians and scientists raced to make a bespoke gene editing therapy for an infant who urgently needed one in months - a first hand account, and what this means for drug development

Gene therapies expert TJ Cradick previews what to watch for at the 2025 ASGCT Annual Meeting in New Orleans

Biotech investor Christoph Broja of EQT Life Sciences discusses biotech in Europe and highlights portfolio companies Tubulis, Agomab Therapeutics, and PanTera

Piper Sandler analyst Biren Amin discusses recent news in ATTR cardiomyopathy, ophthalmology, Duchenne muscular dystrophy, and more

Recent Posts

Join the BiotechTV mailing list

Follow BiotechTV

Sponsors

Sponsor Spotlight